Abstract 857
Background
Colonoscopy is recommended as preferred test for first-degree relatives (FDRs) of colorectal cancer (CRC) patients. However, colonoscopy screening rate remains low. A systematic review and meta-analysis conducted by the research team show that tailored communication is an effective approach to increase uptake of colonoscopy. However, the decision rules that guide the tailored process remain unclear. Based on the identified evidences, a mHealth intervention with an integrated tailoring decision system was developed. This study aimed to test the feasibility and acceptability of this mHealth intervention in Chinese FDRs.
Methods
A single-blinded, family-based cluster randomized controlled trial was conducted. 20 families with CRC patients were randomized to intervention (10 families, n = 11) or control group (10 families, n = 10). Intervention consists of 3 sessions that provided tailored cancer and screening messages on response of personal assessment. All participants received an e-brochure on CRC and CRC screening. Feasibility was measured by recruitment and completion rate, whereas acceptability was assessed by a self-developed questionnaire.
Results
34.5% of eligible family members agreed to participate. 70% of participants completed the trial and all of them completed 3 sessions. All the participants satisfied with the intervention, and agreed the intervention help them understand their risks and appropriate screening recommendations. The main reason for low recruitment rate is that cancer cases were contacted through phone to identify FDRs. Even this is a common strategy when conducting family trials, it is difficult to obtain the trust of FDRs by phone due to the adverse influence of phone scam.
Conclusions
It is acceptable to provide mHealth intervention to Chinese FDRs. However, family recruitment utilizing cancer registry-identified cases seems less feasible in Chinese population. Recruitment through direct contact with FDRs is recommended, for example, through current screening program or clinical units. Furthermore, a definitive trial to test the effectiveness of developed intervention is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bai Yang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract